Skip to main content
NOVOGENE CO., LTD. logo

NOVOGENE CO., LTD. — Investor Relations & Filings

Ticker · 688315 ISIN · CNE1000052X3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 558 across all filing types
Latest filing 2022-09-14 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688315

About NOVOGENE CO., LTD.

https://www.novogene.com

Novogene Co., Ltd. is a global provider of genomic services and solutions, specializing in next-generation sequencing (NGS) and bioinformatics analysis. The company offers a comprehensive suite of services, including whole genome sequencing, transcriptomics, epigenomics, and metagenomics, alongside specialized solutions for single-cell analysis and clinical diagnostics. Utilizing advanced high-throughput sequencing platforms and proprietary bioinformatics pipelines, Novogene supports research across diverse fields such as human health, agriculture, and environmental science. The organization serves a broad client base encompassing academic institutions, pharmaceutical companies, and biotechnology firms. With a focus on data quality and technical expertise, Novogene facilitates large-scale genomic studies and precision medicine initiatives through its network of high-capacity laboratories and integrated data management systems.

Recent filings

Filing Released Lang Actions
发行人及保荐机构关于北京诺禾致源科技股份有限公司向特定对象发行股票申请文件的审核问询函的回复报告
Capital/Financing Update Classification · 95% confidence The document is a detailed response report to an inquiry letter from the Shanghai Stock Exchange regarding a company's application for a specific stock issuance to targeted investors. It contains extensive information about the company's fundraising project, including the use of proceeds, project necessity, business expansion, capacity utilization, and compliance. The document discusses the company's capital raising activities and the specifics of the financing plan, which aligns with a capital or financing update. It is not an annual report, earnings release, or management report, but rather a regulatory response related to a capital raising event. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a mere announcement but a substantive filing related to financing.
2022-09-14 Chinese
立信会计师事务所（特殊普通合伙）关于北京诺禾致源科技股份有限公司向特定对象发行股票申请文件的审核问询函的回复
Capital/Financing Update Classification · 95% confidence The document is a detailed response to an inquiry letter from the Shanghai Stock Exchange regarding a company's application for a private placement of shares (向特定对象发行股票). It includes extensive financial and operational details about the proposed fundraising, including the scale of financing, use of proceeds, investment in laboratory equipment, and financial projections. The document is lengthy (15,000 characters) and contains substantive financial data and analysis related to a capital raising event. It is not a simple announcement or a brief summary but a comprehensive report addressing regulatory questions about the financing and investment plans. Therefore, it fits best into the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2022-09-14 Chinese
北京市中伦律师事务所关于北京诺禾致源科技股份有限公司2022年度向特定对象发行A股股票的补充法律意见书（一）
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding a company's 2022 private placement of A shares. It includes extensive legal and compliance review related to the issuance, including responses to regulatory inquiries, updates on the issuance approval and authorization, and detailed disclosures about the use of proceeds and compliance with laws. The document is not a financial report, earnings release, or management discussion, but a legal opinion supporting a capital raising transaction. It is not a brief announcement but a substantive legal opinion document. This fits the category of Capital/Financing Update (CAP), as it relates to the company's fundraising activity and legal compliance for a specific share issuance.
2022-09-14 Chinese
北京市中伦律师事务所关于北京诺禾致源科技股份有限公司2022年度向特定对象发行A股股票的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter issued by a law firm regarding a company's 2022 private placement of A shares. It extensively discusses the approval, authorization, legal compliance, and procedural aspects of the company's specific stock issuance to particular investors. The content includes legal verification of the issuance process, shareholder approvals, pricing, issuance conditions, and compliance with relevant laws and regulations. This is not a financial report, earnings release, or management discussion, but a legal opinion related to a capital raising event. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2022-09-14 Chinese
中信证券股份有限公司关于北京诺禾致源科技股份有限公司2022年度向特定对象发行股票之上市保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as a "上市保荐书" (Listing Sponsorship Letter) related to Beijing Novogene Co., Ltd.'s 2022 private placement of A shares. It contains detailed information about the company, its business, financial data, risk factors, issuance details, pricing, and use of proceeds. The document is a formal application and sponsorship letter for a specific capital raising event (private placement of shares) and includes underwriting and regulatory compliance information. It is not a general annual report, earnings release, or management discussion, but rather a detailed capital/financing update related to a specific share issuance. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is substantial and contains substantive financial and operational data related to the financing event, not just an announcement or summary, so it is not an RPA or RNS.
2022-09-14 Chinese
中信证券股份有限公司关于北京诺禾致源科技股份有限公司2022年度向特定对象发行股票之发行保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行保荐书" (Issuance Sponsorship Letter) related to a 2022 specific share issuance of A shares by Beijing Novogene Technology Co., Ltd. It is issued by CITIC Securities as the sponsor and underwriter. The content includes detailed information about the issuer, the sponsor, the issuance process, legal and regulatory compliance, financial data, shareholder structure, and the sponsor's due diligence and recommendation for the issuance. This document is a formal sponsorship letter for a capital raising event (a share issuance to specific investors) and not a financial report, earnings release, or management discussion. It is not a proxy statement, voting result, or merger document. It is a detailed capital/financing update document related to the company's fundraising activity. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence level.
2022-09-14 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.